SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-17-005234
Filing Date
2017-05-09
Accepted
2017-05-09 16:02:19
Documents
47
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q adms10q03312017.htm 10-Q 853490
2 EXHIBIT 10.2 admsq110q2017ex102.htm EX-10.2 76804
3 EXHIBIT 31.1 admsq110q2017ex311.htm EX-31.1 14827
4 EXHIBIT 31.2 admsq110q2017ex312.htm EX-31.2 14846
5 EXHIBIT 32.1 admsq110q2017ex321.htm EX-32.1 9280
  Complete submission text file 0001628280-17-005234.txt   3254448

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT adms-20170331.xml EX-101.INS 527050
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adms-20170331.xsd EX-101.SCH 23977
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT adms-20170331_cal.xml EX-101.CAL 42198
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT adms-20170331_def.xml EX-101.DEF 90116
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adms-20170331_lab.xml EX-101.LAB 310979
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adms-20170331_pre.xml EX-101.PRE 175466
Mailing Address 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608
Business Address 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608 510-450-3554
Adamas Pharmaceuticals Inc (Filer) CIK: 0001328143 (see all company filings)

IRS No.: 421560076 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36399 | Film No.: 17826311
SIC: 2834 Pharmaceutical Preparations